# Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

> **NCT07211178** · — · RECRUITING · sponsor: **Tempus AI** · enrollment: 900 (estimated)

## Conditions studied

- Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- HER2 + Breast Cancer
- Early Stage Breast Cancer

## Interventions

- **OTHER:** There are no interventions in this observational study.

## Key facts

- **NCT ID:** NCT07211178
- **Lead sponsor:** Tempus AI
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2032-12
- **Final completion:** 2033-12
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07211178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07211178, "Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07211178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*